Cancers 11 , 675 (2019)
ALN-2232: Dedicated RNAi program for obesity & weight management (Phase 1 data expected H2 2026) $4.9-$5.3B projected 2026 revenue, fueling aggressive expansion in metabolic and cardiometabolic pipelines 10+ tissue types & 40+ clinical programs targeted by 2030 ~30% of revenues reinvested into R&D, accelerating next-generation metabolic innovation Reinforces obesity's emergence as a foundational pillar of future medicine ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter Todays popular weight-loss drugs (like Wegovy or Zepbound) are GLP-1 agonists
Semaglutide and Tirzepatide also have warnings for the possibility of causing pancreatitis, gallbladder problems, hypoglycemia, acute kidney injury, diabetic retinopathy, increased heart rate, severe gastrointestinal disease, and suicidal behavior or thinking
(2016a) 21:80218
Our team recommends a 3ml syringe with a 21-23g needle for drawing the bacteriostatic water
It's inexpensive, easy to get, and allows for a temporary escape from the madness that surrounds us